Compounds and methods for the treatment of urogenital disorders
The present invention provides methods for treating a variety of urogenital disorders, such as, for example, vaginismus, dyspareunia, vulvodynia (including vulvar vestibulitis), interstitial cystitis, nonspecific urethriris (i.e., nonspecific pain and/or burning of the urinary tract) and sexual dysfunctions, such as, for example, female sexual arousal disorders and female sexual orgasmic disorders, using a variety of compounds, including, but not limited to, NO donors, calcium channel blockers, cholinergic modulators, α-adrenergic receptor antagonists, β-adrenergic receptor agonists, phosphodiesterase inhibitors, cAMP-dependent protein kinase activators (e.g., cAMP mimetics), superoxide scavengers, potassium channel activators, estrogen-like compounds, testosterone-like compounds, benzodiazepines, adrenergic nerve inhibitors, antidiarrheal agents, HMG-CoA reductase inhibitors, smooth muscle relaxants, adenosine receptor modulators, adenylyl cyclase activators, endothelin receptor antagonists, bisphosphonates and cGMP-dependent protein kinase activators (e.g., cGMP mimetics).
1 - 28 . (canceled)
29 . A method for treating interstitial cystitis, the method comprising administering to a patient in need thereof a compound selected from the group consisting of NO donors, β-adrenergic receptor agonists, phosphodiesterase inhibitors, cAMP-dependent protein kinase activators, superoxide scavengers, potassium channel activators, testosterone-like compounds, benzodiazepines, antidiarrheal agents, HMG-CoA reductase inhibitors, smooth muscle relaxants, adenosine receptor modulators, adenylyl cyclase activators and endothelin receptor antagonists.
30 . The method of claim 29 , wherein said method comprises administering to said patient at least two compounds.
31 . The method of claim 29 , wherein said method comprises administering to said patient a second compound selected from the group consisting of calcium channel blockers, cholinergic modulators, α-adrenergic receptor antagonists, estrogen-like compounds, adrenergic nerve inhibitors, cGMP-dependent protein kinase activators and cGMP mimetics.
32 . The method of claim 29 , wherein said compound is administered orally.
33 . The method of claim 29 , wherein said compound is administered parenterally.
34 . The method of claim 29 , wherein said compound is administered installation into the bladder.
35 . The method of claim 29 , wherein said compound is administered topically.
36 . The method of claim 35 , wherein said compound is in a form selected from the group consisting of gel, ointment, cream, lotion, powder, solution, suspension, spray, paste, oil, suppository, and foam.
37 . The method of claim 29 , wherein said compound is delivered continuously.
38 . The method of claim 37 , wherein a vaginal suppository or a ring impregnated with said compound is inserted at the affected site.
39 - 83 . (canceled)